TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06315738: Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)

Sponsor: Noveome Biotherapeutics, formerly Stemnion · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 36 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,114,350

Rescue Site Savings

+$733,125

Unlock Full NCT06315738 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06315738 Rescue Dossier →